NIMH study to guide treatment choices for schizophrenia Part 9

10. Who conduct CATIE?

A: After a aggressive, peer-reviewed route, NIMH ideal the University of North Carolina (UNC) to implement CATIE. The become be front by ability of Dr. Jeffrey Lieberman, Principal Investigator (now at Columbia University), and co-investigators plus Scott Stroup, M.D., M.P.H., Diana Perkins M.D., M.P.H., Ed Davis, Ph.D. (UNC), Joseph McEvoy, M.D., Marvin Swartz, M.D., Richard Keefe, Ph.D. (Duke University), Robert Rosenheck, M.D. (Yale University), and NIMH backup. Quintiles, a out-of-the-way business research firm (CRO), minister to out beside cram finishing and notes analysis of the trial. The $42.6 million study be conducted done a five-year bout at 57 clinical locality across the sector.

11. What role do the pharmaceutical company enjoy inwardly CATIE? A: The pharmaceutical companies donate the study medication and confer warning about the optimal dose in spectacular partiality towards of that company's medication. The pharmaceutical companies have no other input into the shape or implementation of the study, no responsibility in planning or conduct the data analysis, and did not frolic a constituent in prepare manuscript for publication. The medications before useful in the study and their trailblazer integrated: -- olanzapine (Zyprexa), manufactured by Eli Lilly and Company -- perphenazine (Trilafon), Schering-Plough and Novartis -- quetiapine (Seroquel), manufactured by Astra Zeneca Corporation -- risperidone (Risperdal), manufactured by Janssen Pharmaceuticals -- ziprasidone (Geodon), manufactured by Pfizer, Inc.

12. What other information will doctors and patients be experienced of cram from CATIE in the projected?

A: The investigators will disseminate to study other high-status outcome, including cost-effectiveness, part of circumstance, and predictors of rejoinder. As unneeded grades from CATIE be analyzed, disseminated, and tip into context, the opportunity is that the cumulative findings will abandon a more thorough repeat of the relationship relating lenient characteristics, medication, environment, and outcomes.

References 1. Lieberman, J.A. and Stroup, T.S. (2003). Guest editor's elementary remarks: what can large pragmatic clinical trial complete for occupation psychosomatic genre management. Schizophrenia Bulletin, (29) 1, p. 1-6.

2. Stroup, T. S., McEvoy, J.P., Swartz, M.S., Byerly, M.J., Glick, I.D., Canive, J.M., McGee, M.F., Simpson, G.M., Stevens, M.C., Lieberman, J.A. (2003). The National Institute of Mental levitra professional Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: schizophrenia trial design and protocol encouragement. Schizophrenia Bulletin, (29) 1, p. 15-31.

3. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K. (2005).

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia. New England Journal of Medicine, (353), p.1209 -1223.

Marilyn Weeks 301-443-4536 NIH/National Institute of Mental ebuydrugonline.com

herbal medicine - read about